Investing.com - Accelerate Diagnostics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Accelerate Diagnostics announced earnings per share of $-0.180 on revenue of $2.96M. Analysts polled by Investing.com EPS of $-0.200 on revenue of $3.75M.
Accelerate Diagnostics 's are down 71% and is trading at $1.430 , still down 79.14% from its 52 week high of $7.19 set on Monday, November 15, 2021.
Accelerate Diagnostics shares lost 4.67% to trade at $1.430 in after-hours trade the report.
Accelerate Diagnostics follows other major Healthcare sector earnings this month
Accelerate Diagnostics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar